Follow The Filings

INCY Incyte Corporation

Health Care, filed as Incyte Corp. (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 2.6%
  • $1.4B
  • 2 reduce

In 2026 Q2 Harry Burn and Dodge & Cox trimmed Incyte.

Who owns this now

Largest portfolio weights among holders, up to 2.6% (Harry Burn, Sound Shore Management). Not free-float ownership.

  1. Harry Burn Reduce 2.6%
  2. Dodge & Cox Reduce 0.71%

Who owns INCY

Sorted by value, long equity only, as of 2026 Q2.

History
Dodge & Cox 0.71% Reduce −2.4% 11,957,326 $1.4B History
Harry Burn, Sound Shore Management 2.6% Reduce −1.3% 757,723 $86M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by INCY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INCY insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $58.3M sold by 10 insiders under 10b5-1 plans
  1. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $298K 2,642 shares at $112.71 1.4% of stake
    Traded Oct 15 Filed Oct 19
    ↗
  2. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $2.8M 23,218 shares at $120.49 11% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  3. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $1.4M 10,801 shares at $125.56 5.6% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  4. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $1.3M 10,803 shares at $120.04 5.3% of stake
    Traded Aug 12 Filed Aug 14
    ↗
  5. Patrick A Mayes EVP & Chief Scientific Officer
    Planned sale
    $274K 2,207 shares at $123.99 3.5% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  6. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $1.3M 10,640 shares at $122.69 4.9% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  7. Patrick A Mayes EVP & Chief Scientific Officer
    Planned sale
    $5.7M 47,954 shares at $119.58 44% of stake
    Traded Jul 31–Aug 3 Filed Aug 4
    ↗
  8. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $1.9M 15,888 shares at $119.70 6.9% of stake
    Traded Jul 31 Filed Aug 4
    ↗
  9. Mohamed Khairie Issa EVP, Head of U.S. Commercial
    Planned sale
    $126K 1,093 shares at $115.01 1.7% of stake
    Traded Jul 16 Filed Jul 20
    ↗
  10. Steven H Stein CMO & Head of Late-Stage Dev.
    Planned sale
    $215K 1,877 shares at $114.73 8.2% of stake
    Traded Jul 16 Filed Jul 20
    ↗
  11. Steven H Stein CMO & Head of Late-Stage Dev.
    Planned sale
    $3.2M 28,237 shares at $113.05 52% of stake
    Traded Jul 15 Filed Jul 16
    ↗
  12. Thomas Tray Principal Accounting Officer
    Planned sale
    $264K 2,639 shares at $100.00 11% of stake
    Traded Jun 4 Filed Jun 8
    ↗
  13. Thomas Tray Principal Accounting Officer
    Planned sale
    $200K 2,051 shares at $97.35 8.8% of stake
    Traded May 26 Filed May 28
    ↗
  14. Paul J Clancy Director
    Planned sale
    $1.4M 15,000 shares at $94.93 39% of stake
    Traded May 19 Filed May 21
    ↗
  15. Pablo J Cagnoni President, Global Head of R&D
    Planned sale
    $1.8M 18,667 shares at $96.50 6.6% of stake
    Traded Apr 17 Filed Apr 21
    ↗

Also filed in the last 12 months, not counted as buying or selling: 44 option exercises, 41 stock grants, and 28 share withholdings for taxes.

Congress

1 member of Congress traded INCY in the last three years: 0 buys and 1 sale. 1 member listed it in 2025 annual reports.

All Congress trades
  1. Robert P. Bresnahan, Jr. R-PA-8 Sell $1K–$15K May 15, 2025 filed May 31, 2025

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 16 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.7B $4.24B $5.14B
Gross profit * $3.44B $3.93B $4.77B
Gross margin * 93.1% 92.6% 92.8%
Net income $0.598B $0.033B $1.29B
Net margin * 16.2% 0.8% 25.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $4.65B $3.24B $5.02B
Total non-current assets * $2.14B $2.21B $1.93B
Total assets $6.78B $5.44B $6.96B
Total current liabilities $1.24B $1.64B $1.52B
Total non-current liabilities * $351.89M $354.85M $275.32M
Total equity $5.19B $3.45B $5.17B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $0.496B $0.335B $1.41B
Cash from investing -$207.68M $157.52M -$102.61M
Cash from financing -$0.02B -$2.02B $0.101B
Net change in cash $0.262B -$1.53B $1.41B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.